Exemestanum 25mg/tab 50 Tabletten by Nassa Labs

Usage

1. Establish your cycle classification first.: Confirm the cycle lasted 10–16 weeks and involved aromatising compounds at moderate doses — this is the specific context for which this protocol is calibrated.
2. Begin Exemestane at the appropriate start point.: Start PCT approximately 2 weeks after the last injection of a long-ester compound, or 3–5 days after the last dose of a short-ester compound, to allow steroid clearance before estrogen management begins.
3. Run the induction phase at 25mg daily for weeks 1–2.: Take each tablet with a meal containing dietary fat — Exemestane is lipophilic and oral bioavailability improves meaningfully with food, as noted in pharmacokinetic studies.
4. Transition to the step-down phase at week 3.: Shift to 25mg every other day; on non-dosing days, no adjustment is needed given Exemestane's sustained enzyme inactivation duration.
5. Order mid-protocol blood work at week 2.: Serum estradiol (E2) confirmation at the end of the induction phase allows protocol adjustment before the step-down phase begins — this is the key monitoring checkpoint in moderate-cycle PCT.
6. Complete the full protocol duration.: Do not discontinue Exemestane prematurely based on subjective wellbeing alone; moderate cycles require the full 4–6 week recovery window for reliable HPG axis restoration.

Warnings

Frequently asked questions

What does a standard post-cycle protocol look like after a moderate anabolic cycle using Exemestane?

A standard moderate-cycle PCT with Exemestane typically runs 4–6 weeks: 25mg daily for weeks 1–2 (induction phase), then 25mg every other day for weeks 3–6 (step-down phase). Moderate cycles — generally 10–16 weeks with aromatising compounds — produce enough residual aromatase activity to require this phased approach rather than a flat low-dose schedule used after shorter or lighter cycles.

How is the required Exemestane dose different after a moderate cycle compared to a beginner cycle?

After a moderate cycle, estrogen suppression needs are higher and more sustained than after a beginner cycle. A daily 25mg induction phase is typically warranted for the first two weeks, whereas beginner-cycle users often manage with lower or less frequent dosing from day one. The greater aromatase upregulation produced by longer, heavier cycles justifies a stronger opening dose before transitioning to an every-other-day maintenance schedule.

How long does HPG axis recovery typically take after a moderate anabolic cycle when using Exemestane in PCT?

Clinical references and practical protocols suggest HPG axis recovery following a moderate cycle takes approximately 4–6 weeks of structured PCT support. Exemestane's irreversible aromatase inactivation mechanism sustains estradiol control across each dosing interval, supporting consistent conditions for LH and FSH restoration throughout the full recovery window rather than producing fluctuating estrogen levels between doses.

How many tablets does the Nassa Labs 50-tablet pack provide for a complete moderate-cycle PCT?

At standard moderate-cycle dosing — 25mg daily for 2 weeks (14 tablets) then 25mg every other day for 4 weeks (14 tablets) — the total is approximately 28 tablets for a 6-week protocol. The 50-tablet pack therefore covers a full 6-week PCT with meaningful surplus, eliminating the risk of running short mid-recovery, which is a critical practical consideration given that interrupting estrogen management during HPG axis recovery is counterproductive.

Do Nassa Labs Exemestane 25mg tablets need to be split to achieve the every-other-day dosing phase?

No splitting is required for the step-down phase of a moderate-cycle PCT. The every-other-day schedule delivers 25mg per dose — exactly matching the tablet's pre-formed API load — so athletes simply alternate dosing days without cutting tablets. This preserves API integrity and ensures each dose reflects the HPLC-verified content of a complete tablet rather than relying on manual splitting accuracy. (2) angle_used

Manufacturer

Nassa Labs applies a finished-product testing framework to its oral tablet line that is formally separated from production scheduling: for the Exemestane 25mg/tab product specifically, batch clearance is conditional on two independent analytical outcomes — HPLC content quantification of the Exemestane API against a certified reference standard, and a manufacturing-environment endotoxin assessment conducted under LAL methodology. Both results must achieve passing status before the batch is assigned a distribution lot code; neither outcome is treated as subordinate, and neither assessment is initiated on units already allocated for shipment. The facility operates under GMP-compliant procedures applied across the oral solid-dose production line, and each tablet's compression matrix is validated to ensure API uniformity across the tablet population within the lot — a specification that directly supports dosing consistency across the 4–6 week moderate-cycle PCT protocol for which this 50-tablet pack is positioned.